Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48


Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.

Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA.

Front Immunol. 2018 Jan 5;8:1825. doi: 10.3389/fimmu.2017.01825. eCollection 2017. Review.


Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.

Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A.

Front Immunol. 2017 Sep 25;8:1194. doi: 10.3389/fimmu.2017.01194. eCollection 2017. Review.


Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.

Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, Jochem-Kolb H.

Front Immunol. 2017 Jun 7;8:496. doi: 10.3389/fimmu.2017.00496. eCollection 2017. Review.


Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz BS, Relation T, Lee TJ, Lotze MT, Yu JG, Zhang J, Croce CM, Yu J, Caligiuri MA, Old M, Kaur B.

Clin Cancer Res. 2016 Nov 1;22(21):5265-5276. Epub 2016 Jul 7. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1359-1360.


A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry.

Somanchi SS, McCulley KJ, Somanchi A, Chan LL, Lee DA.

PLoS One. 2015 Oct 22;10(10):e0141074. doi: 10.1371/journal.pone.0141074. eCollection 2015.


Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment.

Singh SV, Ajay AK, Mohammad N, Malvi P, Chaube B, Meena AS, Bhat MK.

Cell Death Dis. 2015 Oct 22;6:e1934. doi: 10.1038/cddis.2015.292.


Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, Han Y, Wu H, Meng X, Xu H, Zhan F, Wu X, Shi J.

Oncotarget. 2015 Sep 29;6(29):26982-94. doi: 10.18632/oncotarget.4831.


Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.

Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S.

Front Immunol. 2015 May 13;6:230. doi: 10.3389/fimmu.2015.00230. eCollection 2015. Review.


NK cell-based immunotherapies in Pediatric Oncology.

McDowell KA, Hank JA, DeSantes KB, Capitini CM, Otto M, Sondel PM.

J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93. doi: 10.1097/MPH.0000000000000303. Review.


Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.

Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F.

J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059.


Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.

Sarhan D, D'Arcy P, Lundqvist A.

Int J Mol Sci. 2014 Oct 14;15(10):18557-73. doi: 10.3390/ijms151018557. Review.


Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.

Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, Zhang W, Nie J, Feng K, Chen M, Zhang Y, Wang Y, Shi F, Fu X, Zhu H, Han W.

J Immunol Res. 2014;2014:371087. doi: 10.1155/2014/371087. Epub 2014 May 21.


Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity.

Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, Olive D.

Front Immunol. 2014 Mar 24;5:122. doi: 10.3389/fimmu.2014.00122. eCollection 2014. Review.


Clinical utility of natural killer cells in cancer therapy and transplantation.

Knorr DA, Bachanova V, Verneris MR, Miller JS.

Semin Immunol. 2014 Apr;26(2):161-72. doi: 10.1016/j.smim.2014.02.002. Epub 2014 Mar 5. Review.


A study exploring critical pathways in clear cell renal cell carcinoma.

Zeng Z, Que T, Zhang J, Hu Y.

Exp Ther Med. 2014 Jan;7(1):121-130. Epub 2013 Nov 7.


Immunotherapeutic approaches to treat multiple myeloma.

Roeven MW, Hobo W, Schaap N, Dolstra H.

Hum Vaccin Immunother. 2014;10(4):896-910. Epub 2013 Dec 11. Review.


Tumor-primed NK cells: waiting for the green light.

Sabry M, Lowdell MW.

Front Immunol. 2013 Nov 25;4:408. doi: 10.3389/fimmu.2013.00408. Review.


A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.

Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE 3rd.

J Immunother. 2014 Jan;37(1):55-62. doi: 10.1097/CJI.0000000000000009.


The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.

Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA.

Pharm Res. 2015 Mar;32(3):779-92. doi: 10.1007/s11095-013-1231-0. Epub 2013 Nov 8.

Supplemental Content

Support Center